Marise R Heerma van Voss
Overview
Explore the profile of Marise R Heerma van Voss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
384
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koppen A, Sikma M, Engels F, Heerma van Voss M, Chamuleau M, Bartelink I, et al.
Br J Clin Pharmacol
. 2025 Mar;
PMID: 40070262
No abstract available.
2.
Heerma van Voss M, Molenaar R, Korst C, Bartelink I, Baglio S, Kruyswijk S, et al.
Expert Opin Biol Ther
. 2024 Aug;
24(9):889-901.
PMID: 39185748
Introduction: T-cell redirecting bispecific antibodies (BsAbs), targeting B-cell maturation antigen (BCMA) or G-protein - coupled receptor class C group 5 member D (GPRC5D), are efficacious new agents for the treatment...
3.
Heerma van Voss M, Notohardjo J, van Dodewaard-de Jong J, Bloemendal H, Ter Heine R
Cancer Chemother Pharmacol
. 2024 Jul;
94(3):437-441.
PMID: 38951305
Purpose: Docetaxel is a cytotoxic drug used for first-line treatment of various malignancies. It has a narrow therapeutic index and shows wide interpatient variability in clearance and toxicity. Tools for...
4.
Braat A, Heerma van Voss M, Bijlsma R
Lancet Oncol
. 2021 May;
22(5):e216.
PMID: 33932384
No abstract available.
5.
Heerma van Voss M, Kammers K, Vesuna F, Brilliant J, Bergman Y, Tantravedi S, et al.
Transl Oncol
. 2018 Apr;
11(3):755-763.
PMID: 29684792
DDX3 is an RNA helicase with oncogenic properties. The small molecule inhibitor RK-33 is designed to fit into the ATP binding cleft of DDX3 and hereby block its activity. RK-33...
6.
Tantravedi S, Vesuna F, Winnard Jr P, Heerma van Voss M, van Diest P, Raman V
Oncotarget
. 2018 Feb;
8(70):115280-115289.
PMID: 29383159
When crypt stem cells of the gastrointestinal tract become injured, the result is increased synthesis of pro-inflammatory cytokines and matrix metalloproteinases by their progeny - the colonic epithelium. Chronic inflammation...
7.
Heerma van Voss M, van Diest P, Raman V
Biochim Biophys Acta Rev Cancer
. 2017 Oct;
1868(2):510-520.
PMID: 28965870
Cancer cells are reliant on the cellular translational machinery for both global elevation of protein synthesis and the translation of specific mRNAs that promote tumor cell survival. Targeting translational control...
8.
Heerma van Voss M, Vesuna F, Bol G, Meeldijk J, Raman A, Offerhaus G, et al.
Onco Targets Ther
. 2017 Aug;
10:3501-3513.
PMID: 28761359
Purpose: DEAD box protein 3 (DDX3) is an RNA helicase with oncogenic properties that shuttles between the cytoplasm and nucleus. The majority of DDX3 is found in the cytoplasm, but...
9.
Heerma van Voss M, Brilliant J, Vesuna F, Bol G, van der Wall E, van Diest P, et al.
Med Oncol
. 2017 Feb;
34(3):33.
PMID: 28138868
Triple-negative breast cancers have unfavorable outcomes due to their inherent aggressive behavior and lack of targeted therapies. Breast cancers occurring in BRCA1 mutation carriers are mostly triple-negative and harbor homologous...
10.
Heerma van Voss M, Schrijver W, Ter Hoeve N, Hoefnagel L, Manson Q, van der Wall E, et al.
Clin Exp Metastasis
. 2016 Dec;
34(1):85-92.
PMID: 27999982
Metastatic breast cancer remains one of the leading causes of death in women and identification of novel treatment targets is therefore warranted. Functional studies showed that the RNA helicase DDX3...